Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Arcutis accelerates ARQ-151 into phase III trials for the treatment of atopic dermatitis

Sep. 9, 2020

Arena begins phase II trial of etrasimod for moderate to severe alopecia areata

Sep. 2, 2020

Innovent opens phase I study in China with IBI-112 for autoimmune diseases

Sep. 2, 2020

FDA approves Winlevi for acne

Aug. 27, 2020

Novartis details development of best-in-class LTA4 hydrolase inhibitor LYS-006

Aug. 27, 2020

Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical patent JAK-2, TYK2 inhibitors

Aug. 14, 2020

Phase IIa study of KY-1005 in atopic dermatitis meets primary endpoints

Aug. 11, 2020

Cosentyx approved in the E.U. for pediatric psoriasis

Aug. 3, 2020

Lilly discovers interleukin-17 receptor A antagonists

July 30, 2020

Krystal begins phase III study of beremagene geperpavec for dystrophic epidermolysis bullosa

July 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...